Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q1 2021 financial results on May 4, 2021, after trading closes. Management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can listen in by calling (833) 614-1518 for domestic or (270) 823-1072 for international participants, using Conference ID: 6696232. Pulmonx is known for its minimally invasive treatments for lung diseases, including its Zephyr® Endobronchial Valve, which is available in over 25 countries and has been used in more than 80,000 devices to treat over 20,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) reported a full year 2020 revenue of $32.7M, a marginal increase of 0.4% year-over-year. U.S. revenue surged 51% to $16.2M, while international revenue fell 24% to $16.5M. The fourth quarter saw total revenue decline 5% to $9.8M. Operating expenses spiked 41% to $16.4M, resulting in a net loss of $9.3M. Looking ahead, the company expects 2021 revenue between $46M and $50M, reflecting 41%-53% growth.
Pulmonx Corporation (NASDAQ: LUNG) will release its financial results for Q4 and full year 2020 on March 2, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company focuses on minimally invasive treatments for severe emphysema, with its Zephyr® Endobronchial Valve approved by the FDA as a breakthrough device. The valve has been utilized in over 20,000 patients worldwide. For more details, visit their investor webpage.
On January 28, 2021, JTV, a national jewelry retailer, announced its partnership with the Respiratory Health Association and Pulmonx Corporation for the third annual Catch Your Breath® campaign. This initiative aims to raise awareness and funds for women's lung disease during February 2021, focusing on educational opportunities about lung health. The campaign includes a special event from January 29 to 31, where 50% of sales from the Catch Your Breath® butterfly jewelry collection will benefit lung health programs.
Pulmonx Corporation (NASDAQ: LUNG) has welcomed Georgia Garinois-Melenikiotou and Thomas W. Burns to its Board of Directors as part of its initial public offering in October 2020. Garinois-Melenikiotou brings significant experience in global consumer marketing from her tenure at Estée Lauder and Johnson & Johnson, while Burns offers over 25 years of experience in medical technology, currently serving as CEO of Glaukos Corporation. Their expertise is expected to enhance Pulmonx's efforts in expanding its market presence for innovative treatments for severe lung disease.
Pulmonx Corporation announced that over 20,000 patients have been treated globally with its Zephyr® Endobronchial Valves, the first FDA-approved minimally invasive treatment for severe emphysema. This treatment significantly improves lung function, exercise capacity, and overall quality of life without the risks associated with traditional surgery. Dr. D. Kyle Hogarth highlighted the Zephyr Valve's role in helping patients breathe easier. The device is now included in national and global COPD treatment guidelines, evidencing its acceptance and effectiveness in clinical practice.
Pulmonx Corporation (Nasdaq: LUNG) reported a 17% increase in revenue for Q3 2020, totaling $10.6 million. The gross margin remained stable at 70.3%. U.S. revenue surged by 57% to $5.3 million, driven by the Zephyr Valve launch, while international revenue dropped 8% due to pandemic impacts. Operating expenses rose 28% to $12.8 million, leading to a net loss of $3.9 million or $1.37 per share. Pulmonx expects full-year revenue between $31.5-$32.0 million, reflecting ongoing uncertainty from COVID-19.
Pulmonx Corporation (NASDAQ: LUNG) announced its participation in two virtual investor conferences. The company will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 10:40 a.m. ET, with a live and archived webcast available on its website. Additionally, Pulmonx management will join investor meetings at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. Pulmonx specializes in minimally invasive treatments for severe emphysema, having received FDA pre-market approval for its Zephyr Endobronchial Valve.
Pulmonx Corporation (NASDAQ: LUNG) announced that Health Care Service Corporation (HCSC) has implemented a positive coverage policy for the Zephyr Endobronchial Valve effective November 1, 2020. This policy benefits Blue Cross Blue Shield members across Illinois, Montana, New Mexico, Oklahoma, and Texas. The Zephyr Valve offers a minimally invasive treatment for severe emphysema, improving lung function and quality of life without major surgery. Over 20,000 patients have been treated with this valve globally, highlighting its significance in COPD management.
Pulmonx Corporation (NASDAQ: LUNG) will release its third-quarter financial results on November 10, 2020, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company specializes in minimally invasive treatments for lung disease, particularly for severe emphysema/COPD patients. The Zephyr® Endobronchial Valve, part of its treatment solutions, has received FDA pre-market approval and is available in over 25 countries with more than 80,000 valves used on over 20,000 patients.